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ABSTRACT
BACKGROUND The few randomized controlled trials (RCTs) on chronic total occlusion (CTO) percutaneous coronary
intervention (PCI) are subject to selection bias.
OBJECTIVES The purpose of this study was to evaluate the differences between real-world CTO patients and those
enrolled in RCTs.
METHODS This study performed a meta-analysis of national and dedicated CTO PCI registries and compared patient
characteristics and outcomes with those of RCTs that randomized patients to CTO PCI versus medical therapy. Given the
large sample size differences between RCTs and registries, the study focused on the absolute numbers and their clinical
signiﬁcance. The study considered a 5% relative difference between groups to be potentially clinically relevant.
RESULTS From 2012 to 2022, 6 RCTs compared CTO PCI versus medical therapy (n ¼ 1,047) and were compared with 15
registries (5 national and 10 dedicated CTO PCI registries). Compared with registry patients, RCT patients had fewer
comorbidities, including diabetes, hypertension, previous myocardial infarction, and prior coronary artery bypass graft
surgery. RCT patients had shorter CTO length (29.6  19.7 mm vs 32.6  23.0 mm, a relative difference of 9.2%) and
lower Japan–Chronic Total Occlusion Score scores (2.0  1.1 vs 2.3  1.2, a relative difference of 13%) compared with
those enrolled in dedicated CTO registries. Procedural success was similar between RCTs (84.5%) and dedicated CTO
registries (81.4%) but was lower in national registries (63.9%).
CONCLUSIONS There is a paucity of randomized data on CTO PCI outcomes (6 RCTs, n ¼ 1,047). These patients have
lower risk proﬁles and less complex CTOs than those in real-world registries. Current evidence from RCTs may not be
representative of real-world patients and should be interpreted within its limitation.
(J Am Coll Cardiol Intv 2022;15:1441–1449) © 2022 by the American College of Cardiology Foundation.

From the aDivision of Cardiology, Henry Ford Hospital, Detroit, Michigan, USA; bDepartment of Internal Medicine, Hennepin
Healthcare, Minneapolis, Minnesota, USA; cDepartment of Cardiology, University Heart Center Freiburg–Bad Krozingen, Bad
Krozingen, Germany; dDepartment of Cardiology, MediClin Heartcenter Lahr, Lahr, Germany; eDepartment of Cardiology, Klinikum Darmstadt, Darmstadt, Germany; fDepartment of Cardiology, Saint Luke’s Mid America Heart Institute, Kansas City, Missouri; gDepartment of Cardiology, Emory University, Atlanta, Georgia, USA; hDepartment of Cardiology, Columbia University, New
York, New York, USA; and the iMinneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA. *Drs
Megaly and Buda contributed equally to this work.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’
institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information,
visit the Author Center.
Manuscript received February 23, 2022; revised manuscript received April 18, 2022, accepted May 10, 2022.

ISSN 1936-8798/$36.00
https://doi.org/10.1016/j.jcin.2022.05.023
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on August 22, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

1442

Megaly et al

JACC: CARDIOVASCULAR INTERVENTIONS VOL. 15, NO. 14, 2022
JULY 25, 2022:1441–1449

CTO PCI Patients in RCTs vs Registries

T

ABBREVIATIONS
AND ACRONYMS
CTO = chronic total occlusion
MACE = major adverse cardiac
event(s)

he key indication for chronic total

comparing RCT patients with those enrolled in dedi-

occlusion (CTO) percutaneous coro-

cated CTO PCI registries. These registries represent

nary intervention (PCI) is currently

operators with focus and expertise in CTO PCI. The

symptom improvement to the lack of ran-

study’s detailed search strategy and ﬂowchart are

domized data showing improvement of hard

shown in Supplemental Figure 1.

outcomes.1

MI = myocardial infarction

in

PCI = percutaneous coronary

However,

randomized

enrolling

controlled

trials

patients
(RCT)

comparing CTO PCI versus medical therapy

intervention

has been challenging, especially for highly

RCT = randomized controlled

symptomatic and higher-risk patients. This

trial

challenge

has

plagued

coronary

interventional

research and is often reﬂected in poor enrollment,
termination of trials before complete enrolment,
and very high screening-to-enrollment ratios. No
comparison has been performed to date on the characteristics of patients who underwent CTO PCI in
RCTs versus standard clinical practice, which was
the focus of the present study.

OUTCOMES AND DEFINITIONS. The main objective

of our study was to describe and compare the baseline
characteristics and outcomes of patients enrolled in
RCTs versus registries. All baseline variables were
compared between both groups. A CTO was deﬁned
as an atherosclerotic occlusion in one of the treated
vessels, older than 3 months, and TIMI (Thrombolysis
In Myocardial Infarction) ﬂow grade 0. Outcomes
assessed included procedural success, in-hospital
mortality, myocardial infarction (MI), major adverse
cardiac events (MACE), and pericardial tamponade.
Technical success was deﬁned as achieving < 30%
residual diameter stenosis within the treated segment
and restoring TIMI ﬂow grade 3. Procedural success

SEE PAGE 1450

was deﬁned as technical success without MACE

METHODS

deﬁned as death, MI, and urgent revascularization.

SEARCH STRATEGY. We conducted a systematic re-

STATISTICAL ANALYSIS. Given the large sample size

view of studies that included patients who under-

differences between RCTs and registries, we opted

went CTO PCI. We performed a computerized search

not to perform pairwise analysis but focused on the

according to the proposal for conducting and report-

absolute numbers and clinical signiﬁcance of relative

ing MOOSE (Meta-Analyses of Observational Studies) 2

differences between both groups. We considered a 5%

and the PRISMA (Preferred Reporting Items for Sys-

relative difference between groups to be potentially

tematic Reviews and Meta-Analyses) guidelines. 3 We

clinically relevant. We performed a pooled analysis

performed a systematic search limited to the English

using the following meta-analysis method for certain

language through Medline, Embase, and Cochrane

variables, including procedural success and compli-

databases from January 2012 to January 2022 using

cations. We ﬁrst input the total clinical setting per-

the following search terms separately and in combi-

centage for the main variable and number of

“randomized

participants of each study and then calculated the

controlled trial,” “registry,” “CTO,” and “PCI.” We

corresponding 95% CIs using the Byar’s approxima-

screened the retrieved studies’ bibliographies for

tion to the Poisson distribution. Then we pooled ef-

relevant studies not found through the initial search.

fect sizes, which denoted median “rates” and the

Two independent investigators (K.B. and M.M., both

95% CI using the inverse variance method with

physicians) performed the search. The study is a

random effects. We performed the analysis to esti-

systematic review and meta-analysis; therefore, no

mate the 95% CI of that variable. Heterogeneity was

Institutional Review Board approval was required.

reported as I 2 percentage, with I 2 >50% considered

nation:

“chronic

total

occlusion,”

We included all RCTs that randomized patients to

signiﬁcant heterogeneity. The baseline characteristics

CTO PCI versus medical therapy during the study

presented were weighted according to the sample

period. We aimed to compare those patients with

size. Statistical analysis was performed using STATA

contemporary

software for Windows (version 17.0, StataCorp).

real-world

patients

undergoing

CTO PCI. We only included large multicenter registries (n ¼ >1,000) to avoid selection bias that would

RESULTS

possibly originate from including single-center registries. We excluded administrative-based registries,

From 2012 to 2022, 6 published RCTs compared CTO

registries that study speciﬁc populations (eg, elderly),

PCI versus medical therapy and were compared with

and registries with duplicate or overlapping cohorts.

15 registries (5 national registries and 10 dedicated

We compared RCT patients with those enrolled in

CTO PCI registries).

national clinical registries (not dedicated to CTO PCI).
We

then

performed

another

separate

analysis

Details on the included RCTs are shown in
Supplemental Table 1. The 6 RCTs included 1,047
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patients enrolled patients between 2007 and 2017 and

The CTO characteristics (length, calciﬁcation, Japan–

were published between 2016 and 2021. The trials

Chronic Total Occlusion Score [J-CTO] score, etc.)

were performed outside the United States, and 3 of

were not systematically reported in the national reg-

them were single-center RCTs. 4-6 Only one study

istries and could not be further analyzed.

included the presence of viability in akinetic areas

Procedural success was signiﬁcantly lower in na-

among its inclusion criteria. 4 Three RCTs excluded

tional registries compared with RCT patients (63.9%

patients with low left ventricular ejection fraction

vs 84.5%, a relative difference of 24.4%) (Figure 1).

(<25%-30%).4,5,7 Two studies excluded patients with

However, RCT patients had a higher risk of in-

a contraindication to cardiac magnetic resonance. 5,8

hospital events, including death (1.3% vs 0.6%, a

All trials only randomized patients with single-

relative difference of 52.3%), MACE (7.9% vs 1.5%, a

vessel CTOs, although some studies included pa-

relative difference of 81.0%), myocardial infarction

tients with multivessel disease. Two RCTs studied the

(5.9% vs 1.0%, a relative difference of 83.1%), and

impact of CTO PCI on left ventricular ejection fraction

tamponade (0.9% vs 0.3%, a relative difference of

recovery,5,8 3 studied the impact on quality of

66.7%) (Figure 2, Supplemental Figure 2).

life, 4,6,9 and 1 studied the impact on MACE.7 Procedural success ranged from 73% to 90.6%. Trials took a
long time to enroll the required patients ranging from
2 years for small studies 4 to approximately 6 years for
the larger studies. 7 The largest 2 RCTs failed to achieve their target number and stopped enrollment
prematurely. 7,9
Details on the included registries are listed in
Supplemental Table 2. Ten dedicated CTO PCI registries, including 76,067 patients, were included. Publication dates ranged from 2013 to 2021, while
enrollment dates ranged from 2006 to 2019. They
mostly included all-comers with few exclusion
criteria in some registries, including anoxic brain
injury or cancer. Registries included patients worldwide with 2 registries based solely in the United
States,10,11 1 in Japan,12 1 in Latin America, 13 4 in
Europe,14-17 1 in Korea, 18 and 1 multinational. 19 Procedural success ranged from 77.8% to 89.5%.
Five national registries reported outcomes of CTO
PCI, including 110,349 patients. Publication dates
ranged from 2013 to 2021, while enrollment dates
ranged from 2005 to 2018. They also included allcomers with few exclusion criteria in some registries, including anoxic brain injury or cancer. Registries included patients from the United States,20,21 the
United Kingdom,22 Japan,23 and the Netherlands. 24
Procedural success ranged from 58.4% to 78.2%.
COMPARISON

CTO registries are shown in Table 1. There was no
difference in sex or age between both groups. RCT
patients had fewer comorbidities, including diabetes,
hypertension, dyslipidemia, peripheral arterial disease, previous MI, previous PCI, and previous coronary artery bypass grafting. Patients in RCTs were
less likely to present with stable angina (59.6% vs
65.5%, a relative difference of 9.0%). RCT patients
had shorter CTO length (29.6  19.7 mm vs 32.6 
23.0 mm, a relative difference of 9.2%) and lower JCTO scores (2.0  1.1 vs 2.3  1.2, a relative difference
of 13.0%).
Procedural success was similar between both
groups. RCT patients had a higher risk of in-hospital
events, including death (1.3% vs 0.3%, a relative difference of 76.0%), MACE (7.9% vs 1.9%, a relative
difference of 75.9%), myocardial infarction (5.9% vs
1.0%, a relative difference of 83.1%), and tamponade
(0.9% vs 0.8%, a relative difference of 11.1%).
A summary of the study results is shown in the
Central Illustration.

DISCUSSION
Our study is the ﬁrst to compare characteristics of
patients undergoing CTO PCI in the real world and
those randomized in the few CTO PCI RCTs. The main

between patients included in RCTs and national reg-

ﬁndings of our study include: 1) few RCTs have

istries are listed in Supplemental Table 3. RCT pa-

compared CTO PCI versus medical therapy (6 RCTs,

tients were more likely to be men (84.3% vs 76.4%, a

including approximately 1,000 patients), and all have

relative difference of 9.3%). They tended to have

been performed outside the United States; 2) only 3

fewer comorbidities, including diabetes, hyperten-

RCTs were multicenter, and only 1 was powered to

sion, peripheral arterial disease, previous MI, previ-

assess MACE but had high crossover (20%); 3) RCT

ous

bypass

enrollment was slow (range 2-6 years), and the

grafting. RCT patients had longer ﬂuoroscopy times

biggest 2 RCTs did not enroll target sample popula-

and more contrast than patients in national registries.

tion derived from the power calculation and had to be

previous

AND

between patients included in RCTs and dedicated

REGISTRIES. Differences in baseline characteristics

and

RCTs

REGISTRIES. Differences in baseline characteristics

NATIONAL

PCI,

BETWEEN

COMPARISON BETWEEN RCTs AND DEDICATED CTO

coronary

artery
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F I G U R E 1 Forest Plots of Procedural Success and In-Hospital Mortality

Forest plots of (A) procedural success and (B) in-hospital mortality with chronic total occlusion (CTO). PCI ¼ percutaneous coronary intervention; RCT ¼ randomized
controlled trial; REML ¼ random effects maximum likelihood.

stopped prematurely because of slow enrollment; 4)

to date, including approximately 1,000 patients. In

RCT patients had fewer comorbidities and lower risk

addition, none of the trials were powered to detect

proﬁles than those in registries (both national and

difference in harder outcomes such as death and MI.

dedicated CTO registries); 5) RCT patients underwent

CTO PCI has been a very challenging procedure to

CTO PCI for less complex CTOs compared with those

evaluate in randomized trials for many reasons. First,

in dedicated CTO registries, but the procedural suc-

although CTO PCI has grown rapidly in the last 2 de-

cess rate was similar, and complication rates were

cades, there are few operators that can perform it

higher; and 6) compared with national registries, CTO

proﬁciently. Second, the main indication of CTO PCI

PCI performed in dedicated CTO registries was asso-

is to relieve symptoms after the failure of maximum

ciated with higher success rates and lower in-hospital

medical therapy, and highly symptomatic patients are

mortality.

difﬁcult

to

randomize.

For

example,

most

in-

Decision making in current medical practice should

vestigators participating in the European CTO trials

be based on evidence, with RCTs providing the

randomized <10 patients per year, while they would

highest-quality data. In certain areas, the evidence

include over 200 patients into the European CTO

from RCTs is limited; hence, leveraging high-quality

registries, highlighting very high selection bias.

observational studies is needed to evaluate the

Third, limited awareness of treatment options and

impact of treatment strategies. Our study illustrates

conﬂicting data on the beneﬁts and risks of CTO PCI

paucity of RCT evidence in CTO PCI with only 6 RCTs

made patient recruitment slow and difﬁcult. RCTs of
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F I G U R E 2 Forest Plots of Major Adverse Cardiovascular Events and Myocardial Infarction

Forest plots of (A) major adverse cardiovascular events and (B) myocardial infarction with chronic total occlusion percutaneous coronary intervention. Abbreviations as
in Figure 1.

CTO PCI took 2 to 6 years to enroll patients in rela-

to treat their patients in the best way possible, and

tively small studies (n ¼ 94-815). Understanding these

CTO PCI appears to be the preferred treatment for

statistics and difﬁculties would help evaluate the

many such patients. This likely explains why pa-

current evidence reasonably, knowing that the

tients enrolled in RCTs had lower-risk features

paucity of evidence does not necessarily mean that

compared with those included in real-world regis-

the null hypothesis is proven. Moreover, the largest

tries, including fewer comorbidities and complex

RCT performed to date (DECISION-CTO [Drug-Eluting

features of their CTO characteristics (eg, longer CTO

Stent Implantation Versus Optimal Medical Treat-

length, higher J-CTO scores). The difference in risk

ment in Patients With Chronic Total Occlusion]) did

proﬁles sheds light on the limitations of applying

not reach its target enrollment goal, lost statistical

the current RCT results into daily practice, espe-

power, and had high crossover rate from medical

cially when many patients would not fulﬁll the RCT

therapy to CTO PCI (20%), which makes the study

inclusion criteria.

results difﬁcult to interpret.7 To mitigate the need for

In our study, RCT patients had more complications

a large but almost impossible to perform trial pow-

and higher in-hospital mortality than those in real-

ered for mortality, the DECISION-CTO trial used a

world registries (both national and dedicated CTO

composite endpoint including stroke, MI, and repeat

registries). The higher complications reported in RCTs

revascularization that inevitably biased the study

likely highlights the under-reporting of complications

toward the null hypothesis.

in registries, as they are not as strictly adjudicated as

Investigators and clinicians face a dilemma when

RCTs. The difference might also be attributed to

asked to enroll highly symptomatic or higher-risk

standardized follow-up and close monitoring of

patients into RCTs. They have a moral obligation

these

patients

after

the

procedure,

leading to
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T A B L E 1 Comparison of RCTs and Dedicated CTO Registries

Baseline characteristics and hemodynamic
parameters
Age, y
BMI, kg/m2
Male
Diabetes
Hypertension
Dyslipidemia
Active smoking
Peripheral arterial disease
History of stroke
Previous MI
Previous PCI
Previous CABG
Multivessel disease
LVEF, %
SYNTAX score
J-CTO score

RCTs (6)
(n ¼ 1,047)

Dedicated CTO Registries (10)
(n ¼ 76,467)

Relative
Difference (%)

62.44  9.64 (1,047)
26.9  4.1 (827)
84.3
29.4 (975)
65.3 (975)
56.3 (975)
44.3 (975)
7.3 (568)
5.5 (716)
19.7 (975)
26.7 (925)
6.5 (777)
69.3 (777)
53.7  11.4 (975)
20.9  9.6 (716)
2.0  1.1 (975)

64.7  10.2 (76,467)
29.6  5.9 (50,572)
84.0
37.8
82.4
81.6 (75,467)
26.5 (75,104)
12.6 (59,360)
3.4 (23,624)
43.4 (73,196)
54.9
22.1 (75,467)
46.8 (17,086)
50.7  13.3 (46,324)
17.2  9.8 (7,185)a
2.3  1.2 (63,861)

3.5
9.1
0.4
22.2
20.8
31.0
40.1
42.1
38.2
54.6
51.4
70.6
32.5
5.6
17.7
13.0

59.6 (417)
27.3 (417)

65.5 (39,139)
25.0 (38,099)

9.0
8.4

33.2 (975)
15.2 (975)
51.5 (975)
29.6  19.7 (309)
48.0 (508)

26.4
18.7
52.4
32.6  23.0 (39,139)
49.8 (51,865)

20.5
18.7
1.7
9.2
3.6

111.2  59.2 (425)
43.7  32.4 (846)
5,136.8  4,479.7 (425)
313.6  163.3 (846)
2.2  1.2 (846)
68.3  34.4 (846)
84.5 (76.7 to 92.4) (886)

128.0  41.8 (13,249)
43.8  28.2 (13,059)
3,090.1  2,242.7 (8,535)
270.4  112.9 (25,532)
1.9  0.93 (10,367)
52.3  32.4 (11,709)
81.4 (75.6 to 87.1) (41,046)

13.3
0.2
39.8
13.7
13.6
23.4
3.7

1.3 (-0.4 to 3.1) (861)
7.9 (4.8 to 10.9) (712)
5.9 (2.8 to 8.9) (715)
0.9 (-0.4 to 2.3) (966)

0.30 (0.6 to 1.2) (31,350)
1.9 (0.4 to 3.5) (29,685)
1.0 (-0.1 to 2.2) (13,724)
0.8 (-0.5 to 2.1) (9,478)

76.0
75.9
83.1
11.1

Presentation
Stable angina
Unstable angina/ACS
CTO-related artery
LAD
LCx
RCA
CTO length, mm
Moderate-severe calciﬁcation
Procedural characteristics
Procedural time, min
Fluoroscopy time, min
Air kerma, mGy
Contrast, mL
Number of stents
Stent length
Procedural success
In-hospital outcomes
Death
MACE
MI
Tamponade

Values are mean  SD (n), %, % (n), or % (95% CI), unless otherwise indicated. aData reported from 2 studies.
ACS ¼ acute coronary syndrome; BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; CTO ¼ chronic total occlusion; J-CTO ¼ Japan–Chronic Total Occlusion
Score; LAD ¼ left anterior descending artery; LCx ¼ left circumﬂex artery; LM ¼ left main artery; LVEF ¼ left ventricular ejection fraction; MACE ¼ major adverse cardiovascular
event(s); MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; RCA ¼ right coronary artery; RCT ¼ randomized controlled trial; SYNTAX ¼ TAXUS Drug-Eluting
Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries.

reporting complications that may not be reported in

In our analysis, the success rate of CTO PCI was

registries (eg, measuring troponin levels with more

81.4% in dedicated CTO registries and 63.9% in na-

periprocedural MI, reporting nonconsequential per-

tional registries (a relative difference of 17.5%). Pa-

forations). The higher mortality in RCTs might be

tients in dedicated CTO registries also had lower

attributed to operator insistence in pursuing success

mortality compared with those in national registries

given the nature of trial enrollment. Although the

(0.3% vs 0.6%, a relative difference of 51.6%). CTO

under-representation of in-hospital death is possible

PCI is a complex procedure, and previous studies

in registries, it is unlikely to be the reason of such

have shown that success rate depends heavily on

difference. Given the higher number of patients in the

operator volume.25 Our study conﬁrms that the per-

included registries compared with RCTs, the actual

formance of CTO PCI by dedicated high-volume op-

mortality rate of CTO PCI might be better reﬂected by

erators leads to higher success rates and lower

registry ﬁndings, rather than by RCTs.

mortality

rates.

It

should

be

noted
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C ENTR AL I LL U STRA T I ON Summary of the Study Results

Comparative Analysis of Chronic Total Occlusion Patients in
Randomized Trials and Real-World Registries
6 RCTs (n = 1,047) vs. 10 dedicated CTO registries (n = 76,467), 5 national registries (n = 110,349)
RCT Patients Compared With Real-World Registries

Similar procedure success as
dedicated CTO registries
(84.5% vs. 81.4%)

Fewer comorbidities

Higher procedural success than
national registries
(84.5% vs. 63.9%)

Higher in-hospital death
and adverse events
Less complex CTO features
(shorter, lower J-CTO scores)

Patients who had their procedure performed by high-volume operators in dedicated CTO
registries had higher success rates and lower in-hospital death and adverse events
compared with those in national registries

Megaly M, et al. J Am Coll Cardiol Intv. 2022;15(14):1441–1449.

Summary of the comparison between real-world registries and randomized controlled trials (RCTs) of chronic total occlusion (CTO) percutaneous coronary
intervention. J-CTO ¼ Japan–Chronic Total Occlusion Score.

differences mentioned (17.5% and 51.6%) only repre-

to improve hard outcomes. However, data from

sent the difference between dedicated operators and

observational studies suggest potential beneﬁts of

the overall average, and the difference would be

CTO PCI such as improvement of left ventricular

higher if the comparisons were between dedicated

systolic function and systolic wall thickening, 26,27 the

operators and lower-volume nondedicated ones.

positive impact on survival and MACE in successful

The main indication for CTO PCI in current practice

procedures compared with failed ones, 28 and the

is to improve symptoms and quality of life, which has

positive impact of complete revascularization in pa-

been shown in multiple 4,6,9,11 but not in all observa-

tients with CTO. 29 The double jeopardy impact of MI

7

tional studies and RCTs. The limited evidence from

in patients with CTOs should also be considered when

available RCTs does not support performing CTO PCI

making decisions about revascularization.30
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STUDY

LIMITATIONS. First,

we

only

aimed

with those included in registries, but our analyses
were at the study level, as we lacked patient-level
data. Second, further data on procedural details and
CTO characteristics were not systematically reported
in national registries and could not be analyzed.

PERSPECTIVES

Third, the deﬁnitions of periprocedural MI in the

WHAT IS KNOWN? RCTs supporting the impact of

enrolled studies were heterogeneous; therefore, the

CTO PCI on hard outcomes are lacking. A limited

interpretation of MI outcomes should be taken with

number of RCTs have been conducted to compare

caution. Fourth, given the huge sample size differ-

CTO PCI versus medical therapy (6 since 2012),

ence, all comparisons would have likely been statis-

including approximately 1,000 patients.

tically

signiﬁcant,

despite

insigniﬁcant

clinical

difference, which justiﬁed our approach. Finally,
follow-up data were not consistently reported and
could not be analyzed.

CONCLUSIONS
There is a paucity of randomized data on CTO PCI
outcomes (6 RCTs, n ¼ 1,047). These patients have
lower risk proﬁles and less complex CTOs than those
in real-world registries. Albeit considered the highest
level of evidence, current evidence from RCTs may
not be representative of real-world patients and
should be interpreted within its limitation. Dedicated
CTO PCI operators have signiﬁcantly higher success
rates and lower complication rates than nondedicated

WHAT IS NEW? RCT patients have fewer comorbidities with lower risk proﬁles compared with realworld registries. They also underwent CTO PCI for less
complex CTOs compared with those included in
dedicated CTO PCI registries. Procedural complications of CTO PCI might be under-reported in
registries.
WHAT IS NEXT? Current evidence from RCTs is not
representative of real-world patients and should be
interpreted within its limitations. Further RCTs are
required to evaluate the outcomes of CTO PCI in a
representative sample of real-world patients. Meanwhile, leveraging large registries to synthesize highquality evidence is necessary.

operators.
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